Furthermore, while core tumorigenic pathways tend to be rewired, often through mutation, following the application of an antagonistic drug, this does not appear to be the case for sporadic RCC with TSC/mTOR pathway mutations [123]. This evidence concerns the gene MTOR and renal cell carcinoma.